NCT01565694View on ClinicalTrials.gov

A Study to Assess the Long Term Effect, Safety and Metabolism of a Solifenacin Liquid Suspension in Participants 5 to 18 Years of Age With Neurogenic Detrusor Overactivity

PHASE3CompletedINTERVENTIONAL
Enrollment

76

Participants

Timeline

Start Date

August 14, 2012

Primary Completion Date

April 28, 2016

Study Completion Date

April 28, 2016

Conditions
Neurogenic Detrusor Overactivity
Interventions
DRUG

Solifenacin succinate

Oral suspension administered once a day via syringe.

Trial Locations (21)

1015

Site PH6301, Manila

1101

Site PH6302, Quezon City

3526

Site HU3602, Miskolc

6100

Site TR9003, Ankara

8200

Site DK4501, Aarhus

9000

Site BE3201, Ghent

10591

Site US1008, Tarrytown

35100

Site TR9002, Izmir

37000

Site MX5203, León

80803

Site PL4805, Gdansk

110744

Site KR8207, Seoul

120752

Site KR8201, Seoul

45229-3039

Site US1010, Cincinnati

15090-000

Site BR5505, São José do Rio Preto

13060-803

Site BR5507, Campinas

13083-887

Site BR5504, Campinas

80240-060

Site BR5506, Curitiba

90035-903

Site BR5503, Porto Alegre

C.P. 06700

Site MX5205, Mexico City

80-952

Site PL4803, Gdansk

04-730

Site PL4801, Warsaw

All Listed Sponsors
lead

Astellas Pharma Europe B.V.

INDUSTRY

NCT01565694 - A Study to Assess the Long Term Effect, Safety and Metabolism of a Solifenacin Liquid Suspension in Participants 5 to 18 Years of Age With Neurogenic Detrusor Overactivity | Biotech Hunter | Biotech Hunter